surmount-1 tirzepatide non-diabetic obesity weight loss 💊 Could a new medication help reduce complications of obesity? The SURMOUNT-MMO trial investigates tirzepatide, a dual GIP and GLP-1 receptor agonist, in adults with or overweight but without diabetes. Researchers SURMOUNT‐1 study design. This is

If you think you qualify but your provider isnt familiar with the program, you can direct them to the Medicare GLP-1 Bridge information and prior authorization form available through CMS

In these scenarios, a higher-dose B12 supplement (typically 502,000 micrograms daily) or prescribed treatment may be necessary to restore and maintain adequate levels

This is just for reference, as this article focuses specifically on the brand-name drug Victoza compared to Jardiance

Aerobic exercise training-induced irisin secretion is associated with the reduction of arterial stiffness via nitric oxide production in adults with obesity

And so, it takes another step further and it's looking at 11,000 plasma proteins